Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide

Bone Marrow Transplant. 2024 Jan;59(1):131-133. doi: 10.1038/s41409-023-02123-z. Epub 2023 Oct 11.

Authors

Daniel J Ikeda¹, Zachariah DeFilipp^{1

2}, Kerry Collier^{1

2}, Yi-Bin Chen^{1

2}, Bimalangshu R Dey^{1

2}, Areej El-Jawahri^{1

2}, Matthew J Frigault^{1

2}, Mark B Leick^{1

2}, Steven L McAfee^{1

2}, Richard A Newcomb^{1

2}, Paul V O'Donnell^{1

2}, Thomas R Spitzer^{3

4}

Affiliations

¹ Harvard Medical School, Boston, MA, USA.
² Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA. tspitzer@mgh.harvard.edu.
⁴ Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, USA. tspitzer@mgh.harvard.edu.

PMID: 37821533
DOI: 10.1038/s41409-023-02123-z

No abstract available

Publication types

Letter

MeSH terms

Cyclophosphamide / therapeutic use
Hematologic Diseases* / epidemiology
Hematologic Diseases* / prevention & control
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Incidence

Substances

Cyclophosphamide